SEARCH

SEARCH BY CITATION

References

  • 1
    Newall F, Ignjatovic V, Johnston L, Lane G, Cranswick N, Summerhayes R, Monagle P. Unfractionated heparin pharmacokinetic profile in children. J Thromb Haemost 2009; 7 (Suppl. 2): 774.
  • 2
    Kuhle S, Massicotte P, Dinyari M, Vegh P, Mitchell D, Marzinotto V, Chan A, Pieniaszek H, Mitchell L. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005; 94: 116471.
  • 3
    Nowak-Gottl U, Bidlingmaier C, Krumpel A, Gottl L, Kenet G. Pharmacokinetics, efficacy, and safety of LMWHs in venous thrombosis and stroke in neonates, infants and children. Br J Pharmacol 2008; 153: 11207.
  • 4
    Mitchell L, Krumpel A, Barett J, Nowak-Gottl U. Enoxaparin population-pharmacokinetic modelling (pop-PK) in chidren – preliminary results. J Thromb Haemost 2009; 7: 235.
  • 5
    McDonald M, Jacobson L, Hay WJ, Hathaway W. Heparin clearance in the newborn. Pediatr Res 1981; 15: 101518.
  • 6
    Ignjatovic V, Najid S, Newall F, Summerhayes R, Monagle P. Dosing and monitoring of enoxaparin (LMWH) therapy in children. Br J Haematol 2010; 149: 7348.
  • 7
    Ignjatovic V, Newall F, Summerhayes R, Monagle P. The in vitro response to low molecular weight heparin (LMWH) is not age-dependent in children. Thromb Haemost 2010; 103: 8556.
  • 8
    Hiremath M, Ignjatovic V, Newall F, Summerhayes R, Monagle P. The contribution of tissue factor pathway inhibitor to thrombin generation in children receiving unfractionated heparin. Thromb Res 2011; 127: 2756.
  • 9
    Ignjatovic V, Furmedge J, Newall F, Chan A, Berry L, Fong C, Cheng K, Monagle P. Age-related differences in heparin response. Thromb Res 2006; 118: 7415.
  • 10
    Newall F, Ignjatovic V, Johnston L, Lane G, Cranswick N, Monagle P. Clinical use of UFH therapy in children: time for change? Br J Haematol 2010; 150: 6748.
  • 11
    Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, Monagle P. Age is a determinant factor for measures of concentration and effect in children requiring unfractionated heparin. Thromb Haemost 2010; 103: 108590.
  • 12
    Newall F, Ignjatovic V, Summerhayes R, Gan A, Butt W, Johnston L, Monagle P. In vivo age dependency of unfractionated heparin in infants and children. Thromb Res 2009; 123: 71014.
  • 13
    Newall F, Johnston L, Monagle P, Summerhayes R, Lane G, Cranswick N, Ignjatovic V. Novel interations between UFH and TFPI in children. Br J Haematol 2010; 151: 37680.
  • 14
    Doan J, Newall F, Ignjatovic V, Monagle P. Compliance of indicated antithrombotic management at the Royal Children’s Hospital with international guidelines: a 75-day audit. J Thromb Haemost 2009; 7: 1080S; Abstract.
  • 15
    Raschke R, Gollihare B, Peirce J. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Arch Intern Med 1996; 156: 16459.
  • 16
    Raschke R, Reilly B, Guidry J, Fontana J, Srinivas S. The weight-based heparin dosing nomogram compared with a ‘standard care’ nomogram. Ann Intern Med 1993; 119: 87481.
  • 17
    Hirsh J, Bauer K, Donati M, Gould M, Samama M, Weitz J. Parenteral anticoagulants. Chest 2008; 133: S14159.
  • 18
    Chan AK, Black L, Ing C, Brandao LR, Williams S. Utility of aPTT in monitoring unfractionated heparin in children. Thromb Res 2008; 122: 1356.
  • 19
    Ignjatovic V, Summerhayes R, Gan A, Than J, Chan A, Cochrane A, Bennet M, Shann F, Lane G, Ross-Smith M, Monagle P. Monitoring unfractionated heparin (UFH) therapy: which anti-factor Xa assay is appropriate? Thromb Res 2007; 120: 34751.
  • 20
    Chan A, Black L, Ing C, Brandao L, Williams S. Utility of aPTT in monitoring unfractionated heparin in children. Thromb Res 2007; 122: 1356.
  • 21
    Kuhle S, Eulmesekian P, Kavanagh B, Massicotte P, Vegh P, Lau A, Mitchell L. Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 2007; 92: 5547.
  • 22
    Robertson J, Brandao L, Williams S, Ing C, Chan A. Use of a single anti-Xa calibration curve is adequate for monitoring enoxaparin and tinzaparin levels in children. Thromb Res 2008; 122: 8679.
  • 23
    Massicotte P, Sofronas M, DeVeber G. Difficulties in performing clinical trials of antithrombotic therapy in neonates and children. Thromb Res 2006; 118: 15363.